Patents by Inventor Brad St. Croix
Brad St. Croix has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170101464Abstract: The present invention provides, inter alia, methods for treating or ameliorating the effects of a disease, such as cancer, in a subject. The methods include: administering to a subject in need thereof (a) a therapeutically effective amount of a monoclonal antibody or antigen binding fragment of the present invention, and (b) a therapeutically effective amount of a combination therapy including bevacizumab and at least one additional therapeutic agent; or a therapeutically effective amount of at least one additional therapeutic agent selected from the group consisting of a COX-2 inhibitor (COXIB), a non-steroidal anti-inflammatory drug (NSAID), a prostaglandin E2 (PGE2) synthase inhibitor, and combinations thereof. Compositions, including pharmaceutical compositions, and kits for treating diseases, such as cancer, are also provided herein.Type: ApplicationFiled: June 9, 2015Publication date: April 13, 2017Inventors: Saurabh Saha, Xiaoyan M. Zhang, Dimiter Dimitrov, Zhongyu Zhu, Brad St. Croix, Enrique Zudaire
-
Publication number: 20170095575Abstract: The present invention provides, inter alia, methods for treating or ameliorating the effects of a disease, such as cancer in a subject. The methods include: administering to a subject in need thereof (a) a therapeutically effective amount of a molecularly targeted agent; and (b) a therapeutically effective amount of a monoclonal antibody or antigen binding fragment thereof, wherein the monoclonal antibody contains: (i) a heavy chain variable region (VH), which includes an amino acid sequence selected from SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5, and SEQ ID NO:7; and (ii) a light chain variable region (VL), which includes an amino acid sequence selected from SEQ ID NO:2, SEQ ID NO:4, SEQ ID NO:6, and SEQ ID NO:8. Compositions, including pharmaceutical compositions, and kits for treating diseases, such as cancer, are also provided herein.Type: ApplicationFiled: June 9, 2015Publication date: April 6, 2017Applicants: BIOMED VALLEY DISCOVERIES, INC., THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OFInventors: Saurabh Saha, Xiaoyan M. Zhang, Dimiter Dimitrov, Zhongyu Zhu, Brad St. Croix, Enrique Zudaire
-
Publication number: 20160319016Abstract: The present invention is directed to particular antibodies and fragments thereof that find use in the detection, prevention and treatment of diseases and disorders associated with abnormal angiogenesis. In particular, these antibodies detect tumor endothelial marker 8 (TEM8) in its native and cell-surface expressed form. Also disclosed are improved methods for producing monoclonal antibodies, as well as pharmaceutical compositions and kits.Type: ApplicationFiled: April 4, 2016Publication date: November 3, 2016Applicants: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVInventors: Arthur E. FRANKEL, Yunpeng SU, Brad ST.CROIX, Stephen H. LEPPLA
-
Publication number: 20160264662Abstract: Antibodies that specifically bind TEM8 protein, conjugates thereof, and their use, are disclosed herein. In some examples the conjugates and antibodies are useful for methods of detecting and treating pathogenic angiogenesis. In other examples the conjugates and antibodies are useful for methods of detecting and treating cancer. In additional examples, the conjugates and antibodies are useful for methods of decreasing binding of Anthrax protective antigen to a cell.Type: ApplicationFiled: October 13, 2014Publication date: September 15, 2016Applicants: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV, BIOMED VALLEY DISCOVERIES, INC.Inventors: Dimiter Dimitrov, Zhongyu Zhu, Brad St. Croix, Enrique Zudaire, Saurabh Saha, Xiaoyan Michelle Zhang, Gary Decrescenzo, Dean Welsch
-
Publication number: 20160194720Abstract: Methods of inhibiting pathological angiogenesis in a subject are disclosed. In particular examples, the method includes administering a therapeutically effective amount of a composition to a subject wherein the composition includes a specific binding agent that preferentially binds to one or more pathological angiogenesis marker proteins including Vscp, CD276, ETSvg4 (Pea3), CD137(4-1BB), MiRP2, Ubiquitin D (Fat10), Doppel (prion-PLP), Apelin, Plgf, Ptprn (IA-2), CD109, Ankylosis, and collagen VIII?1. In additional examples, methods to deliver a therapeutic agent to a brain or liver endothelial cell are also disclosed.Type: ApplicationFiled: November 30, 2015Publication date: July 7, 2016Applicant: The United States of America, as represented by the Secretary, Department of Health and Human ServInventors: Brad St. Croix, Steven Seaman
-
Patent number: 9309322Abstract: The present invention is directed to particular antibodies and fragments thereof that find use in the detection, prevention and treatment of diseases and disorders associated with abnormal angiogenesis. In particular, these antibodies detect tumor endothelial marker 8 (TEM8) in its native and cell-surface expressed form. Also disclosed are improved methods for producing monoclonal antibodies, as well as pharmaceutical compositions and kits.Type: GrantFiled: November 14, 2011Date of Patent: April 12, 2016Assignee: Scott & White Healthcare (SWH)Inventors: Arthur E. Frankel, Yunpeng Su, Brad St. Croix, Stephen H. Leppla
-
Patent number: 9181340Abstract: Antibodies that specifically bind TEM8 protein, and conjugates thereof, are disclosed herein. In some examples the conjugates and antibodies are useful for methods of detecting and treating pathogenic angiogenesis. In other examples the conjugates and antibodies are useful for methods of detecting and treating cancer. In additional examples, the conjugates and antibodies are useful for methods of decreasing binding of Anthrax protective antigen to a cell.Type: GrantFiled: June 13, 2012Date of Patent: November 10, 2015Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Novartis AGInventors: Brad St. Croix, Tony Fleming, Amit Chaudhary, Saurabh Saha, Xiaoyan Michelle Zhang, Rou-fun Kwong, Mary Beth Hilton
-
Publication number: 20140134179Abstract: Antibodies that specifically bind TEM8 protein, and conjugates thereof, are disclosed herein. In some examples the conjugates and antibodies are useful for methods of detecting and treating pathogenic angiogenesis. In other examples the conjugates and antibodies are useful for methods of detecting and treating cancer. In additional examples, the conjugates and antibodies are useful for methods of decreasing binding of Anthrax protective antigen to a cell.Type: ApplicationFiled: June 13, 2012Publication date: May 15, 2014Applicants: Novartis AG, The United States of America, as represented by the Sec., Dept of Health and Human ServicesInventors: Brad St. Croix, Tony Fleming, Amit Chaudhary, Saurabh Saha, Xiaoyan Michelle Zhang, Rou-fun Kwong
-
Publication number: 20130323173Abstract: The present invention is directed to particular antibodies and fragments thereof that find use in the detection, prevention and treatment of diseases and disorders associated with abnormal angiogenesis. In particular, these antibodies detect tumor endothelial marker 8 (TEM8) in its native and cell-surface expressed form. Also disclosed are improved methods for producing monoclonal antibodies, as well as pharmaceutical compositions and kits.Type: ApplicationFiled: November 14, 2011Publication date: December 5, 2013Applicant: The Government of the United States of America, as Represented by the Secretary, Department of HealtInventors: Arthur E. Frankel, Yuripeng Su, Brad St. Croix
-
Patent number: 8440411Abstract: Methods of inhibiting pathological angiogenesis in a subject are disclosed. In particular examples, the method includes administering a therapeutically effective amount of a composition to a subject wherein the composition includes a specific binding agent that preferentially binds to one or more pathological angiogenesis marker proteins including Vscp, CD276, ETSvg4 (Pea3), CD137(4-1BB), MiRP2, Ubiquitin D (Fat10), Doppel (prion-PLP), Apelin, Plgf, Ptprn (IA-2), CD109, Ankylosis, and collagen VIII?1. In additional examples, methods to deliver a therapeutic agent to a brain or liver endothelial cell are also disclosed.Type: GrantFiled: March 21, 2011Date of Patent: May 14, 2013Assignee: The United States of America as Represented by the Secretary of the Department of Health and Human ServicesInventors: Brad St. Croix, Steven Seaman
-
Publication number: 20110207141Abstract: Methods of inhibiting pathological angiogenesis in a subject are disclosed. In particular examples, the method includes administering a therapeutically effective amount of a composition to a subject wherein the composition includes a specific binding agent that preferentially binds to one or more pathological angiogenesis marker proteins including Vscp, CD276, ETSvg4 (Pea3), CD137(4-1BB), MiRP2, Ubiquitin D (Fat10), Doppel (prion-PLP), Apelin, Plgf, Ptprn (IA-2), CD109, Ankylosis, and collagen VIII?1. In additional examples, methods to deliver a therapeutic agent to a brain or liver endothelial cell are also disclosed.Type: ApplicationFiled: March 21, 2011Publication date: August 25, 2011Inventors: Brad St. Croix, Steven Seaman
-
Publication number: 20110104059Abstract: To gain a better understanding of tumor angiogenesis endothelial cells (ECs) were isolated and gene expression patterns were evaluated. When transcripts from ECs derived from normal and malignant colorectal tissues were compared with transcripts from non-endothelial cells, over 170 genes predominantly expressed in the endothelium were identified. Comparison between normal- and tumor-derived endothelium revealed differentially expressed genes, including many that were specifically elevated in tumor-associated endothelium. Experiments with representative genes from this group demonstrated that most were similarly expressed in the endothelium of primary lung, breast, brain, and pancreatic cancers as well as in metastatic lesions of the liver. These results demonstrate that neoplastic and normal endothelium in humans are distinct at the molecular level.Type: ApplicationFiled: May 6, 2009Publication date: May 5, 2011Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Brad ST. CROIX, Kenneth W. KINZLER, Bert VOGELSTEIN
-
Publication number: 20100028256Abstract: Methods of inhibiting pathological angiogenesis in a subject are disclosed. In particular examples, the method includes administering a therapeutically effective amount of a composition to a subject wherein the composition includes a specific binding agent that preferentially binds to one or more pathological angiogenesis marker proteins including Vscp, CD276, ETSvg4 (Pea3), CD137(4-1BB), MiRP2, Ubiquitin D (Fat10), Doppel (prion-PLP), Apelin, Plgf, Ptprn (IA-2), CD109, Ankylosis, and collagen VIII?1. In additional examples, methods to deliver a therapeutic agent to a brain or liver endothelial cell are also disclosed.Type: ApplicationFiled: June 28, 2007Publication date: February 4, 2010Inventors: Brad St. Croix, Steven Seaman
-
Publication number: 20090233270Abstract: To gain a better understanding of tumor angiogenesis, new techniques for isolating endothelial cells (ECs) and evaluating gene expression patterns were developed. When transcripts from ECs derived from normal and malignant colorectal tissues were compared with transcripts from non-endothelial cells, over 170 genes predominantly expressed in the endothelium were identified. Comparison between normal- and tumor-derived endothelium revealed many differentially expressed genes, including a large nujber of genes that were specifically elevated in tumor-associated endothelium. Experiments with representative genes from this group demonstrated that most were similarly expressed in the endothelium of primary lung, breast, brain, and pancreatic cancers as well as in metastatic lesions fo the liver. Theses results demonstrate that neoplastic and normal endothelium in humans are distinct at the molecular level, and have significant implications for the development of anti-angiogenic.Type: ApplicationFiled: July 2, 2003Publication date: September 17, 2009Inventors: Brad St. Croix, Kenneth Kinzler, Bert Vogelstein
-
Publication number: 20090017030Abstract: To gain a better understanding of tumor angiogenesis, new techniques for isolating endothelial cells (ECs) and evaluating gene expression patterns were developed. When transcripts from ECs derived from normal and malignant colorectal tissues were compared with transcripts from non-endothelial cells, over 170 genes predominantly expressed in the endothelium were identified. Comparison between normal- and tumor-derived endothelium revealed 79 differentially expressed genes, including 46 that were specifically elevated in tumor-associated endothelium. Experiments with representative genes from this group demonstrated that most were similarly expressed in the endothelium of primary lung, breast, brain, and pancreatic cancers as well as in metastatic lesions of the liver. These results demonstrate that neoplastic and normal endothelium in humans are distinct at the molecular level, and have significant implications for the development of anti-angiogenic therapies in the future.Type: ApplicationFiled: October 31, 2007Publication date: January 15, 2009Applicant: The John Hopkins UniversityInventors: Brad St.Croix, Bert Vogelstein, Kenneth W. Kinzler
-
Patent number: 7402660Abstract: To gain a better understanding of tumor angiogenesis, new techniques for isolating endothelial cells (ECs) and evaluating gene expression patterns were developed. When transcripts from ECs derived from normal and malignant colorectal tissues were compared with transcripts from non-endothelial cells, over 170 genes predominantly expressed in the endothelium were identified. Comparison between normal- and tumor-derived endothelium revealed 79 differentially expressed genes, including 46 that were specifically elevated in tumor-associated endothelium. Experiments with representative genes from this group demonstrated that most were similarly expressed in the endothelium of primary lung, breast, brain, and pancreatic cancers as well as in metastatic lesions of the liver. These results demonstrate that neoplastic and normal endothelium in humans are distinct at the molecular level, and have significant implications for the development of anti-angiogenic therapies in the future.Type: GrantFiled: August 1, 2001Date of Patent: July 22, 2008Assignee: The Johns Hopkins UniversityInventors: Brad St. Croix, Bert Vogelstein, Kenneth W. Kinzler
-
Patent number: 7393932Abstract: To gain a better understanding of tumor angiogenesis, new techniques for isolating endothelial cells (ECs) and evaluating gene expression patterns were developed. When transcripts from ECs derived from normal and malignant colorectal tissues were compared with transcripts from non-endothelial cells, over 170 genes predominantly expressed in the endothelium were identified. Comparison between normal- and tumor-derived endothelium revealed 79 differentially expressed genes, including 46 that were specifically elevated in tumor-associated endothelium. Experiments with representative genes from this group demonstrated that most were similarly expressed in the endothelium of primary lung, breast, brain, and pancreatic cancers as well as in metastatic lesions of the liver. These results demonstrate that neoplastic and normal endothelium in humans are distinct at the molecular level, and have significant implications for the development of anti-angiogenic therapies in the future.Type: GrantFiled: April 10, 2002Date of Patent: July 1, 2008Assignee: The Johns Hopkins UniversityInventors: Eleanor Carson-Walter, Brad St. Croix, Kenneth W. Kinzler, Bert Vogelstein
-
Patent number: 7358351Abstract: To gain a better understanding of tumor angiogenesis, new techniques for isolating endothelial cells (ECs) and evaluating gene expression patterns were developed. When transcripts from ECs derived from normal and malignant colorectal tissues were compared with transcripts from non-endothelial cells, over 170 genes predominantly expressed in the endothelium were identified. Comparison between normal- and tumor-derived endothelium revealed 79 differentially expressed genes, including 46 that were specifically elevated in tumor-associated endothelium. Experiments with representative genes from this group demonstrated that most were similarly expressed in the endothelium of primary lung, breast, brain, and pancreatic cancers as well as in metastatic lesions of the liver. These results demonstrate that neoplastic and normal endothelium in humans are distinct at the molecular level, and have significant implications for the development of anti-angiogenic therapies in the future.Type: GrantFiled: November 3, 2004Date of Patent: April 15, 2008Assignee: The Johns Hopkins UniversityInventors: Brad St. Croix, Bert Vogelstein, Kenneth W. Kinzler
-
Publication number: 20060275287Abstract: A scroll compressor that is easy of back pressure adjustment and capable of realizing high compression efficiency. The scroll compressor comprises a plurality of compression spaces formed by fixed spiral blades meshing with rotary spiral blades, a back pressure chamber disposed on the side opposite to the rotary spiral blade surface of the rotary spiral member, high and medium pressure spaces obtained by partitioning the back pressure chamber by seal members, a first passageway for feeding lubricating oil, which is fed to the high pressure space, to the medium pressure space, a second passageway for feeding lubricating oil, which is fed to the medium pressure space, to the suction space of the compression space, wherein the first passageway is intermittently put in communication by the rotary movement of a rotary spiral member.Type: ApplicationFiled: June 23, 2003Publication date: December 7, 2006Inventors: Brad St Croix, Kenneth Kinzler, Bert Vogelstein
-
Publication number: 20060210975Abstract: To gain a better understanding of tumor angiogenesis, new techniques for isolating endothelial cells (ECs) and evaluating gene expression patterns were developed. When transcripts from ECs derived from normal and malignant colorectal tissues were compared with transcripts from non-endothelial cells, over 170 genes predominantly expressed in the endothelium were identified. Comparison between normal- and tumor-derived endothelium revealed many differentially expressed genes, including a large nujber of genes that were specifically elevated in tumor-associated endothelium. Experiments with representative genes from this group demonstrated that most were similarly expressed in the endothelium of primary lung, breast, brain, and pancreatic cancers as well as in metastatic lesions fo the liver. Theses results demonstrate that neoplastic and normal endothelium in humans are distinct at the molecular level, and have significant implications for the development of anti-angiogenic.Type: ApplicationFiled: July 2, 2003Publication date: September 21, 2006Inventors: Brad St Croix, Kenneth Kinzler, Bert Vogelstein